Novavax Inc. NasdaqGS: NVAX
There have been a ton of insider buys for NVAX over the past six months, with only a single sell. The positive news from the company is very reassuring. So much so for current investors, the stock has been setting new 52 week highs lately.
They are getting strong support in the medical community as this release showcases quite nicely: Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013 – (August 28th)
I am not going to list all that they have in the pipeline – and the status for all of their drugs. The press release of August 8th showcases it all nicely. Also, the have $40.6 million in cash to do what they need to do.
Stanley Erck, the President and CEO of the Company, had these comments in the August 8th conference call:
“So the second quarter. The second quarter events including up to now, I think, might have been the most productive quarter we’ve had yet. In April, we announced a new Phase II data for RSV in women. In July, we announced data from an RSV trial in the elderly and exploiting our core technology we began a ground-breaking program for a vaccine candidate against new emerging virus in China, which is H7N9. In parallel, we have responded to and are responding to a new threat coming out of the Middle East and Europe, the coronavirus now called MERS-CoV standing for Middle East Respiratory Syndrome.”
We’re very comfortable with NVAX in our twelve.